M&A Deal Summary

Mirum Acquires Satiogen

On May 23, 2022, Mirum acquired life science company Satiogen

Acquisition Highlights
  • This is Mirum’s 1st transaction in the Life Science sector.
  • This is Mirum’s 1st transaction in the United States.
  • This is Mirum’s 1st transaction in California.

M&A Deal Summary
Date 2022-05-23
Target Satiogen
Sector Life Science
Buyer(s) Mirum
Deal Type Add-on Acquisition

Target

Satiogen

Del Mar, California, United States
website
Satiogen operates as a virtual company by outsourcing all activities required to validate the bile acid brake concept. Its focus has been on preclinical experiments for proof of concept, on collaborating in clinical trials that confirm effects in humans, and on assembling an intellectual property portfolio. Satiogen was formed in 2007 and is based in Del Mar, California.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mirum

Foster City, California, United States

website

Category Company
Founded 2018
Sector Life Science
Revenue 19M USD (2021)
DESCRIPTION

Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. The company's approved medication is LIVMARLI (maralixibat) oral solution which is approved in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum was formed in 2018 and is based in Foster City, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Mergr

Product

Company

Legal